Torsten Hoffmann

Torsten has over 20 years of international R&D leadership experience gained in a number of high-profile pharma and biotech companies, amongst them Roche, Zealand Pharma, and Taros. He is the inventor of the anti-emetic medicine Akynzeo® that was approved in 2014. At Roche and over the course of 8 years he delivered 50+ new lead series, funneled 30+ small molecules into regulatory tox studies, and brought more than 25+ NCEs into clinical studies.

Torsten has contributed more than 95 publications to the community. His research is focused on small molecules, peptides, and RNAi therapeutics.

Beyond being an outstanding expert in drug candidate design, progression of molecules into clinical development and R&D management, he is a brilliant communicator.